

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection No software was used.

Data analysis Figures and statistical analyses were done by using R packages.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The sequencing data are publicly available on The 1000 Genomes Project website (<http://www.1000genomes.org/data>). The PGx information in this study can be accessed from public PGx resources: Drug Bank (<http://www.drugbank.ca/>); PharmGKB (<https://www.pharmgkb.org/>); PharmaADME (<http://www.pharmaadme.org/joomla/>); Biotransformation (Visscher et al, 2009, The Pharmacogenomics Journal; Maisano Delsler and Fuselli, 2013, Human Genetics). All analyzed data is available from the authors upon request. This study analyzed the public-domain data and was approved by Institute Review Board on Biomedical Science Research, Academia Sinica (approval number: AS-IRB01-17025).

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size      The 1000 Genomes Project generated a rich whole-genome sequencing dataset consisting of more than 77 million SNVs in 2,504 individuals from 26 global populations.

Data exclusions      No samples were excluded.

Replication      We only analyzed The 1000 Genomes Project dataset.

Randomization      This is an observational study, not an experimental study. Randomization is not needed.

Blinding      This is an observational study, not an experimental study. Blinding is not needed.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a | Involved in the study

Antibodies

Eukaryotic cell lines

Palaeontology and archaeology

Animals and other organisms

Human research participants

Clinical data

Dual use research of concern

### Methods

n/a | Involved in the study

ChIP-seq

Flow cytometry

MRI-based neuroimaging

## Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics      We are interested in the covariate - genetic ancestry group.

Recruitment      All the samples were recruited by The 1000 Genomes Project.

Ethics oversight      This study analyzed the public-domain data and was approved by Institute Review Board on Biomedical Science Research, Academia Sinica (approval number: AS-IRB01-17025).

Note that full information on the approval of the study protocol must also be provided in the manuscript.